Literature DB >> 718254

Pharmacokinetics and metabolite-pattern of 8-methoxypsoralen in man following oral administration as compared to the pharmacokinetics in rat and dog.

U Busch, J Schmid, F W Koss, H Zipp, A Zimmer.   

Abstract

Following oral administration of 14C labelled 8-methoxypsoralen (8-MOP) in man the plasma level course, the metabolite-patterns and the elimination of the parent compound and its metabolites have been investigated. Additionally the results discovered have been compared with the data of pharmacokinetics on dog and rat. In man and rat the plasma protein binding of 8-MOP has been determined. Maximal levels of the total radioactivity in the plasma were achieved 2 h after dosing. At this time 8-MOP represents 50% of the radioactivity in the plasma. The plasma protein binding in vitro of 14C 8-MOP valued from 88% to 91% in man, and between 75% and 83% in the rat. Urinary elimination of the total radioactivity as a measure of the extent of absorption varies greatly and depends on the therapeutic formulation being employed. Following the administration of the solution 74% is recovered within 48 h. Faecal elimination of the total radioactivity reached 14% within 3 days. The metabolite-pattern does not show the unchanged 14C 8-MOP. Several polar metabolites occur in the urine among which biochemical conjugates have been recognized. Only polar metabolites are observable in the faeces from which the radioactivity is incompletely extractable. From a comparison of the metabolite profiles, the rat as well as the dog seem to be a useful animal species for experimental investigations with 8-MOP.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 718254     DOI: 10.1007/bf00447362

Source DB:  PubMed          Journal:  Arch Dermatol Res        ISSN: 0340-3696            Impact factor:   3.017


  3 in total

1.  Clinical and experimental studies with 8-methoxypsoralen in vitiligo.

Authors:  A B LERNER; C R DENTON; T B FITZPATRICK
Journal:  J Invest Dermatol       Date:  1953-04       Impact factor: 8.551

2.  8-Methoxypsoralen: its isolation and gas chromatographic determination from aqueous solutions and serum.

Authors:  J Gazith; H Schaefer
Journal:  Biochem Med       Date:  1977-08

3.  Photochemotherapy of psoriasis with oral methoxsalen and longwave ultraviolet light.

Authors:  J A Parrish; T B Fitzpatrick; L Tanenbaum; M A Pathak
Journal:  N Engl J Med       Date:  1974-12-05       Impact factor: 91.245

  3 in total
  11 in total

1.  [8-Methoxypsoralen (8-MOP)-a new galenic form and its relation to 8-MOP serum levels (author's transl)].

Authors:  V Nitsche; M Raff; H Bardach
Journal:  Arch Dermatol Res       Date:  1981       Impact factor: 3.017

2.  Photochemotherapeutic agent 8-methoxypsoralen induces cytochrome P450 3A4 and carboxylesterase HCE2: evidence on an involvement of the pregnane X receptor.

Authors:  Jian Yang; Bingfang Yan
Journal:  Toxicol Sci       Date:  2006-09-26       Impact factor: 4.849

3.  Difference in bioavailability between two brands of 8-methoxypsoralen and its impact on the clinical response in psoriatic patients.

Authors:  M J Herfst; F A De Wolff
Journal:  Br J Clin Pharmacol       Date:  1982-04       Impact factor: 4.335

4.  Microenema of 8-methoxypsoralen in photochemotherapy of psoriasis.

Authors:  A H Siddiqui; L Stolk; H R Korthals Altes-Levij van Vinninghe; A Kammeijer; R H Cormane
Journal:  Arch Dermatol Res       Date:  1982       Impact factor: 3.017

5.  Determination of 8-methoxypsoralen levels in plasma and skin suction blister fluid by a new sensitive fluorodensitometric method.

Authors:  H C Korting; M Schäfer-Korting; E Roser-Maass; E Mutschler
Journal:  Arch Dermatol Res       Date:  1982       Impact factor: 3.017

6.  Ocular kinetics of 8-methoxypsoralen. An experimental study with pigmented and albino rabbits without UVA-stimulation.

Authors:  L Salminen; G Wilén
Journal:  Albrecht Von Graefes Arch Klin Exp Ophthalmol       Date:  1981

Review 7.  Clinical pharmacokinetics of methoxsalen and other psoralens.

Authors:  F A de Wolff; T V Thomas
Journal:  Clin Pharmacokinet       Date:  1986 Jan-Feb       Impact factor: 6.447

8.  Intake of Furocoumarins and Risk of Skin Cancer in 2 Prospective US Cohort Studies.

Authors:  Weiyi Sun; Megan S Rice; Min K Park; Ock K Chun; Melissa M Melough; Hongmei Nan; Walter C Willett; Wen-Qing Li; Abrar A Qureshi; Eunyoung Cho
Journal:  J Nutr       Date:  2020-06-01       Impact factor: 4.798

9.  The metabolism of 8-methoxypsoralen in man.

Authors:  J Schmid; A Prox; A Reuter; H Zipp; F W Koss
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1980       Impact factor: 2.441

10.  Influenced of food on the kinetics of 8-methoxypsoralen in serum and suction blister fluid in psoriatic patients.

Authors:  M J Herfst; F A De Wolff
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.